The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Martin, A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Martin, A.
Related Collections
* Autism
* Atypical Neuroleptics
Am J Psychiatry 161:1125-1127, June 2004
© 2004 American Psychiatric Association


Brief Report

Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data

Andrés Martin, M.D., M.P.H., Lawrence Scahill, M.S.N., Ph.D., George M. Anderson, Ph.D., Michael Aman, Ph.D., L. Eugene Arnold, M.D., James McCracken, M.D., Christopher J. McDougle, M.D., Elaine Tierney, M.D., Shirley Chuang, M.S., and Benedetto Vitiello, M.D. the Research Units on Pediatric Psychopharmacology Autism Network

OBJECTIVE: The authors examined the developmental impact and temporal characteristics of risperidone-associated weight change. METHOD: Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months. Change in serum leptin levels after 2 months was examined as a predictor of final weight gain in mixed regression models that controlled for site, gender, age, and risperidone dose. RESULTS: Age- and gender-standardized weight increased after 6 months of treatment (gross: mean=5.6 kg [SD=3.9]; standardized: mean=0.6 z [SD=0.5]) and was positively correlated with weight gained after 1 month. Change in leptin levels after 2 months of treatment (mean=–0.3 ng/ml, SD=6.2) (N=48) did not predict final weight gain. CONCLUSIONS: Chronic risperidone exposure in children with autism causes weight gain in excess of developmentally expected norms that follows a curvilinear trajectory and decelerates over time. Serum leptin change does not reliably predict risperidone-associated weight gain.




This article has been cited by other articles:


Home page
Evid. Based Ment. HealthHome page
B. Vitiello
Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive behaviour disorders.
Evid. Based Ment. Health, November 1, 2006; 9(4): 105 - 105.
[Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
Research Units on Pediatric Psychopharmacology Aut
Risperidone Treatment of Autistic Disorder: Longer-Term Benefits and Blinded Discontinuation After 6 Months
Am J Psychiatry, July 1, 2005; 162(7): 1361 - 1369.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org